1. Home
  2. BXC vs EVO Comparison

BXC vs EVO Comparison

Compare BXC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluelinx Holdings Inc.

BXC

Bluelinx Holdings Inc.

N/A

Current Price

$60.76

Market Cap

706.5M

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

N/A

Current Price

$1.71

Market Cap

568.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BXC
EVO
Founded
2004
1993
Country
United States
Germany
Employees
1700
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
706.5M
568.6M
IPO Year
2004
2007

Fundamental Metrics

Financial Performance
Metric
BXC
EVO
Price
$60.76
$1.71
Analyst Decision
Buy
Buy
Analyst Count
4
3
Target Price
★ $88.33
$4.21
AVG Volume (30 Days)
★ 148.2K
68.2K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.54
N/A
Revenue
N/A
N/A
Revenue This Year
$5.56
N/A
Revenue Next Year
$4.54
$20.17
P/E Ratio
$137.94
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.78
$1.33
52 Week High
$93.80
$3.87

Technical Indicators

Market Signals
Indicator
BXC
EVO
Relative Strength Index (RSI) 32.26 57.74
Support Level $47.84 $1.50
Resistance Level $62.94 $1.97
Average True Range (ATR) 5.15 0.06
MACD -1.24 0.03
Stochastic Oscillator 2.92 66.67

Price Performance

Historical Comparison
BXC
EVO

About BXC Bluelinx Holdings Inc.

BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh, and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: